When are type 1 diabetic patients at risk for cardiovascular disease?

Current Diabetes Reports

Volumn 10, Issue 1, 2010, Pages 48-54

  Orchard, Trevor J ^a   Costacou, Tina ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular disease risk; Glycemia; Haptoglobin; Risk factors; Type 1 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A1; CD163 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HAPTOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METHIONINE SULFOXIDE; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIMARY PREVENTION; REVIEW; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERGLYCEMIA; RISK FACTORS;

EID: 77249094498     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0089-3     Document Type: Review

References (53)

1. TJ Orchard T Costacou A Kretowski RW Nesto 2006 Type 1 diabetes and coronary artery disease Diabetes Care 29 2528 2538 10.2337/dc06-1161 17065698 (Pubitemid 44912266)
2. T Jensen K Borch-Johnsen A Kofoed-Enevoldsen T Deckert 1987 Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence and risk factors Diabetologia 30 144 148 10.1007/BF00274218 1:STN:280:DyaL2s3hvFGqsA%3D%3D 3582820 (Pubitemid 17056998)
3. DM Nathan PA Cleary JY Backlund, et al. 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2643 2653 10.1056/NEJMoa052187 16371630 (Pubitemid 41817713)
4. MM Averill KE Bornfeldt 2009 Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes Curr Diab Rep 9 18 25 10.1007/s11892-009-0005-x 1:CAS:528:DC%2BD1MXltVSksbc%3D 19192420
5. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group DM Nathan B Zinman, et al. 2009 Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005) Arch Intern Med 169 1307 1316 10.1001/archinternmed.2009.193 19636033 This paper describes the improved long-term cumulative risk of major diabetes complications after intensive therapy and compares DCCT conventional treatment results with those seen in the Pittsburgh EDC study
6. CT Prince DJ Becker T Costacou, et al. 2007 Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) Diabetologia 50 2280 2288 10.1007/s00125-007-0797-7 1:STN:280:DC%2BD2srosFagsA%3D%3D 17768606 (Pubitemid 47512402)
7. G Pambianco T Costacou D Ellis, et al. 2006 The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience Diabetes 55 1463 1469 10.2337/db05-1423 1:CAS:528:DC%2BD28XksFahtbY%3D 16644706 (Pubitemid 44195388)
8. AP Levy I Hochberg K Jablonski, et al. 2002 Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study J Am Coll Cardiol 40 1984 1990 10.1016/S0735-1097(02) 02534-2 12475459 (Pubitemid 35425366)
9. M Suleiman D Aronson R Asleh, et al. 2005 Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction Diabetes 54 2802 2806 10.2337/diabetes.54.9.2802 1:CAS:528:DC%2BD2MXhtVSjs7jE 16123372 (Pubitemid 41233605)
10. A Roguin W Koch A Kastrati, et al. 2003 Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes Diabetes Care 26 2628 2631 10.2337/diacare.26.9.2628 12941730 (Pubitemid 37052111)
11. AP Levy HC Gerstein R Miller-Lotan, et al. 2004 The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes Diabetes Care 27 2767 10.2337/diacare.27.11.2767 15505023
12. U Milman S Blum C Shapira, et al. 2008 Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial Arterioscler Thromb Vasc Biol 28 341 347 10.1161/ATVBAHA.107. 153965 1:CAS:528:DC%2BD1cXosVyhuw%3D%3D 18032779 This randomized clinical trial demonstrated more than a 50% reduction in cardiovascular events with vitamin E supplementation among individuals with the susceptible Hp 2-2 genotype (Pubitemid 351161209)
13. BH Bowman A Kurosky 1982 Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation Adv Hum Genet 12 189 261 1:CAS:528:DyaL38XlslOjtLc%3D 6751044
14. Bowman BH: Haptoglobin. In Hepatic Plasma Proteins. Edited by Bowman BH. San Diego: Academic Press; 1993:159-167.
15. MR Langlois JR Delanghe 1996 Biological and clinical significance of haptoglobin polymorphism in humans Clin Chem 42 1589 1600 1:CAS:528: DyaK28Xmt1eqs70%3D 8855140
16. R Asleh S Marsh M Shilkrut, et al. 2003 Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease Circ Res 92 1193 1200 10.1161/01.RES.0000076889.23082.F1 1:CAS:528:DC%2BD3sXkt12qtLY%3D 12750308 (Pubitemid 36723646)
17. R Asleh J Guetta S Kalet-Litman, et al. 2005 Haptoglobin genotype-and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo Circ Res 96 435 441 10.1161/01.RES.0000156653.05853.b9 1:CAS:528:DC%2BD2MXhs12isL4%3D 15662028 (Pubitemid 40354537)
18. AP Levy KR Purushothaman NS Levy, et al. 2007 Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability Circ Res 101 106 110 10.1161/CIRCRESAHA.107.149435 1:CAS:528:DC%2BD2sXntVCitb4%3D 17525367 (Pubitemid 47094629)
19. R Asleh AP Levy 2005 In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease Vasc Health Risk Manag 1 19 28 10.2147/vhrm.1.1.19.58930 1:CAS:528:DC%2BD28Xhtlars7nK 17319095
20. R Asleh S Blum S Kalet-Litman, et al. 2008 Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype Diabetes 57 2794 2800 10.2337/db08-0450 1:CAS:528:DC%2BD1MXhs1Knt7o%3D 18599520 This study demonstrates that the Hp 2-2 genotype and diabetes interact to promote HDL dysfunction. It further shows that vitamin E administration improves HDL function in individuals with diabetes carrying the Hp 2-2 genotype
21. A Schwartz S Blum R Asleh, et al. 2009 Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction Pharmacogenomics and Personalized Medicine 2 1 8 1:CAS:528:DC%2BD1MXpt1yqtLw%3D
22. T Costacou RE Ferrell TJ Orchard 2008 Haptoglobin genotype and renal disease progression in type 1 diabetes Diabetes 57 1702 1706 10.2337/db08-0095 1:CAS:528:DC%2BD1cXnsF2is7k%3D 18332093
23. FM Nakhoul R Zoabi Y Kanter, et al. 2001 Haptoglobin phenotype and diabetic nephropathy Diabetologia 44 602 604 10.1007/s001250051666 1:CAS:528:DC%2BD3MXivVSis7o%3D 11380078 (Pubitemid 32411276)
24. BR Conway DA Savage HR Brady AP Maxwell 2007 Association between haptoglobin gene variants and diabetic nephropathy: haptoglobin polymorphism in nephropathy susceptibility Nephron Exp Nephrol 105 e75 e79 10.1159/000098563 1:CAS:528:DC%2BD2sXhtlKgtL0%3D 17220636 (Pubitemid 46438566)
25. T Costacou 2009 Orchard TJ: Renal hyperfiltration in relation to low renal function and incidence of overt nephropathy among individuals with type 1 diabetes [abstract] Diabetologia 52 Suppl 1 S414
26. A Möllsten M Lajer A Jorsal L Tarnow 2009 The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes Mol Genet Metab 97 80 84 10.1016/j.ymgme.2009.01.013 19246226
27. SS Soedamah-Muthu N Chaturvedi DR Witte, et al. 2008 Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS) Diabetes Care 31 1360 1366 10.2337/dc08-0107 1:CAS:528:DC%2BD1cXpt1Wrs7g%3D 18375412
28. JC Zgibor GA Piatt K Ruppert, et al. 2006 Deficiencies of cardiovascular risk prediction models for type 1 diabetes Diabetes Care 29 1860 1865 10.2337/dc06-0290 16873793 (Pubitemid 44156643)
29. S Gusso P Hofman S Lalande, et al. 2008 Impaired stroke volume and aerobic capacity in female adolescents with type 1 and type 2 diabetes mellitus Diabetologia 51 1317 1320 10.1007/s00125-008-1012-1 1:CAS:528: DC%2BD1cXmslWhu70%3D 18446317
30. EJ Mayer-Davis B Ma A Lawson, et al. 2009 Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering Metab Syndr Relat Disord 7 89 95 10.1089/met.2008.0046 1:CAS:528:DC%2BD1MXlt1Cqtr0%3D 18847385
31. M McGill L Molyneaux SM Twigg DK Yue 2008 The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 22 18 23 10.1016/j.jdiacomp.2006.10.005 18191073
32. LM Thorn C Forsblom J Wadén, et al. 2009 Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes Diabetes Care 32 950 952 10.2337/dc08-2022 19196885
33. J Guy L Ogden RP Wadwa, et al. 2009 Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study Diabetes Care 32 416 420 10.2337/dc08-1775 1:CAS:528:DC%2BD1MXjvVyqtr8%3D 19092167
34. JW Brock AJ Jenkins TJ Lyons, et al. 2008 Increased methionine sulfoxide content of apoA-I in type 1 diabetes J Lipid Res 49 847 855 10.1194/jlr.M800015- JLR200 1:CAS:528:DC%2BD1cXjvFegsLY%3D 18202432
35. F Johansson F Kramer S Barnhart, et al. 2008 Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice Proc Natl Acad Sci U S A 105 2082 2087 10.1073/pnas.0709958105 1:CAS:528:DC%2BD1cXitl2lsrg%3D 18252823
36. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al.: Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31(Suppl 1):S61-S78.
37. JK Snell-Bergeon C Chartier-Logan DM Maahs, et al. 2009 Adults with type 1 diabetes eat a high-fat atherogenic diet that is associated with coronary artery calcium Diabetologia 52 801 809 10.1007/s00125-009-1280-4 1:CAS:528:DC%2BD1MXktVOktLs%3D 19219420
38. I Strychar JS Cohn G Renier, et al. 2009 Effects of a diet higher in carbohydrate/lower in fat versus lower in carbohydrate/higher in monounsaturated fat on postmeal triglyceride concentrations and other cardiovascular risk factors in type 1 diabetes Diabetes Care 32 1597 1599 10.2337/dc08-2322 1:CAS:528:DC%2BD1MXht1agtrzN 19542011
39. WR Hiatt 2008 Aspirin for prevention of cardiovascular events BMJ 337 a1806 10.1136/bmj.a1806 18927172
40. J Belch A MacCuish I Campbell, et al. 2008 The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 a1840 10.1136/bmj.a1840 18927173
41. JK Snell-Bergeon D Dabelea LG Ogden, et al. 2008 Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus J Clin Endocrinol Metab 93 2142 2148 10.1210/jc.2007-2025 1:CAS:528:DC%2BD1cXntFamtrs%3D 18349069 (Pubitemid 351831528)
42. MA Zimmerman SC Flores 2009 Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes J Surg Res 155 173 178 10.1016/j.jss.2008.04.026 1:CAS:528: DC%2BD1MXnsFSjsb0%3D 18805553
43. JW Nin I Ferreira CG Schalkwijk, et al. 2009 Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study Diabetologia 52 705 714 10.1007/s00125-009-1263-5 1:STN:280:DC%2BD1M7mvFSksw%3D%3D 19183936
44. AS Astrup L Tarnow L Pietraszek, et al. 2008 Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate Diabetes Care 31 1170 1176 10.2337/dc07-1960 1:CAS:528:DC%2BD1cXotVantro%3D 18332153
45. M Lajer L Tarnow A Jorsal, et al. 2008 Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy Diabetes Care 31 747 752 10.2337/dc07-1762 1:CAS:528:DC%2BD1cXltVKhtb0%3D 18162497
46. RG Miller CT Prince R Klein TJ Orchard 2009 Retinal vessel diameter and the incidence of coronary artery disease in type 1 diabetes Am J Ophthalmol 147 653 660 10.1016/j.ajo.2008.10.004 19152873
47. JK Snell-Bergeon DM Maahs LG Ogden, et al. 2009 Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease Diabetes Technol Ther 11 1 9 10.1089/dia.2008.0040 1:CAS:528: DC%2BD1MXktlWqtg%3D%3D 19132849
48. N Katakami M Matsuhisa H Kaneto, et al. 2009 Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes Atherosclerosis 204 288 292 10.1016/j.atherosclerosis.2008.08.026 1:CAS:528:DC%2BD1MXlsVKgu74%3D 18926539
49. A Jorsal L Tarnow A Flyvbjerg, et al. 2008 Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy Diabetologia 51 2100 2107 10.1007/s00125-008-1123-8 1:CAS:528:DC%2BD1cXht1amsrnO 18719882
50. TJ Orchard JC Olson JR Erbey, et al. 2003 Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study Diabetes Care 26 1374 1379 10.2337/diacare.26.5.1374 12716791 (Pubitemid 36929165)
51. JA Lykke L Tarnow HH Parving, et al. 2008 A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes Scand J Clin Lab Invest 68 654 659 10.1080/00365510802018330 1:STN:280:DC%2BD1M3os12mug%3D%3D 19378439
52. S Lacigova L Bartunek D Cechurova, et al. 2009 Influence of cardiovascular autonomic neuropathy on atherogenesis and heart function in patients with type 1 diabetes Diabetes Res Clin Pract 83 26 31 10.1016/j.diabres.2008.09.007 19013660
53. M Rosengård-Bärlund L Bernardi J Fagerudd, et al. 2009 Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia 52 1164 1172 10.1007/s00125-009-1340-9 19340407